Nordic Life Science offer cost efficient independent business valuations of Life Science companies and its assets. Our constituents are found both on the buy side and the sell side. Valuations are executed both for management and board of corporations and for venture as well as Private Equity funds. Fair value is often a part in an M & A assignment. A valuation may be required in a licensing negotiation, portfolio management, legal or tax proceeding or as part of a strategic review. An independent valuation is also useful when an owner evaluate possible ways of transition of ownership while planning for a generation shift.